LLY

885.61

-0.67%↓

NVO

141.01

+0.18%↑

UNH

484.21

+0.76%↑

JNJ

147.77

+1.43%↑

MRK

129.72

+1.41%↑

LLY

885.61

-0.67%↓

NVO

141.01

+0.18%↑

UNH

484.21

+0.76%↑

JNJ

147.77

+1.43%↑

MRK

129.72

+1.41%↑

LLY

885.61

-0.67%↓

NVO

141.01

+0.18%↑

UNH

484.21

+0.76%↑

JNJ

147.77

+1.43%↑

MRK

129.72

+1.41%↑

LLY

885.61

-0.67%↓

NVO

141.01

+0.18%↑

UNH

484.21

+0.76%↑

JNJ

147.77

+1.43%↑

MRK

129.72

+1.41%↑

LLY

885.61

-0.67%↓

NVO

141.01

+0.18%↑

UNH

484.21

+0.76%↑

JNJ

147.77

+1.43%↑

MRK

129.72

+1.41%↑

Search

Aclaris Therapeutics Inc

Geschlossen

1.12 -0.88

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.1

Max

1.16

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+76.99 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2024

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Aclaris Therapeutics Inc Chart

Ähnliche Nachrichten

20. Juni 2024, 23:05 UTC

Wichtige Markttreiber

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

20. Juni 2024, 22:45 UTC

Market Talk

QBE's North America Mid-Market Business Closure Is Positive -- Market Talk

20. Juni 2024, 22:40 UTC

Market Talk

Europe's Power-Price Volatility Creates Investment Opportunities -- Market Talk

20. Juni 2024, 22:29 UTC

Market Talk

Limited Near-Term Impact on Helia If It Loses CBA Contract -- Market Talk

20. Juni 2024, 21:37 UTC

Market Talk

Mexican Cabinet Appointments Send Message of Continuity -- Market Talk

20. Juni 2024, 21:18 UTC

Top News

Fed's Barkin Says Inflation to Linger as Rate Hikes Take Full Effect -- Barrons.com

20. Juni 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

20. Juni 2024, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

20. Juni 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Juni 2024, 20:49 UTC

Top News

Nasdaq, S&P 500 Pull Back From Records -- WSJ

20. Juni 2024, 20:21 UTC

Market Talk

Global Energy Roundup: Market Talk

20. Juni 2024, 20:21 UTC

Market Talk

Sun Country to Cut 2025 Passenger Flying Amid Oversupply -- Market Talk

20. Juni 2024, 20:16 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20. Juni 2024, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20. Juni 2024, 19:42 UTC

Market Talk

SPDR Gold Rises on Geopolitical Issues -- Market Talk

20. Juni 2024, 19:25 UTC

Market Talk

Crude Futures Settle Higher on Bullish U.S. Inventories -- Market Talk

20. Juni 2024, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Sink As Heat Eases -- Market Talk

20. Juni 2024, 19:22 UTC

Market Talk

Weak Europe Solar Market Prompts Target Cuts on SolarEdge, Enphase -- Market Talk

20. Juni 2024, 18:51 UTC

Ergebnisse

Obesity-Drug Developers Look at What's Next for a $100 Billion Market -- Barrons.com

20. Juni 2024, 18:45 UTC

Ergebnisse

Emerson Electric Stock Powers Up Amid Rising Profits, Sales -- IBD

20. Juni 2024, 18:09 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20. Juni 2024, 17:56 UTC

Market Talk

Hawkish Emerging Markets Face Recession Risk -- Market Talk

20. Juni 2024, 17:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Juni 2024, 17:03 UTC

Market Talk

Medium Income Homebuyers Need Large Downpayments To Afford Monthly Mortgage -- Market Talk

20. Juni 2024, 16:29 UTC

Market Talk

Oil Gains on U.S. Crude Stocks Draw -- Market Talk

20. Juni 2024, 16:28 UTC

Market Talk

U.S. Home-Sale Prices Hit High, But Buyers Gaining Some Power -- Market Talk

20. Juni 2024, 16:24 UTC

Ergebnisse

Gilead Stock Jumps. Its Twice-Yearly Shot Prevents HIV. -- Barrons.com

20. Juni 2024, 16:23 UTC

Market Talk

Gold Futures Rise as U.S. Data Supports Case for Interest Rate Cut -- Market Talk

20. Juni 2024, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

20. Juni 2024, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Aclaris Therapeutics Inc Prognose

Kursziel

By TipRanks

76.99% Vorteil

12-Monats-Prognose

Durchschnitt 2 USD  76.99%

Hoch 2 USD

Tief 2 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Aclaris Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

2 ratings

0

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

1.01 / 1.13Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bearish Evidence